# A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

> **NCT02055066** · PHASE1 · COMPLETED · sponsor: **argenx** · enrollment: 24 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** ARGX-111

## Key facts

- **NCT ID:** NCT02055066
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055066, "A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02055066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*